
Genetic Technologies Limited (GTG) is diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product is BREVAGenplus. In May 2019, the Company announced that it had developed two new cancer risk assessment tests branded as ‘GeneType for Colorectal Cancer' and ‘GeneType for Breast Cancer'